Kuros Biosciences Ltd. Logo

Kuros Biosciences Ltd.

Develops biologic technologies for tissue repair and bone regeneration.

KURN | SW

Overview

Corporate Details

ISIN(s):
CH0325814116
LEI:
5299006U5POB2AVTT709
Country:
Switzerland
Address:
Wagisstraße 25, 8952 Schlieren

Description

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 02:00
Kuros Biosciences increases the annual guidance for 2025, The company reports 7…
English 12.7 KB
2025-09-18 02:00
Kuros statement on media inquiry concerning former Board member
English 7.6 KB
2025-09-04 02:00
Kuros Biosciences announces changes in the Board of Directors
English 7.4 KB
2025-08-14 02:00
Kuros Biosciences Reports First Half of 2025 Results
English 22.7 KB
2025-03-11 01:00
Kuros Biosciences grows sales to CHF 75.6 million for 2024
English 19.2 KB
2025-01-08 07:00
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 07:00
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 01:00
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 11.8 KB
2024-11-19 07:00
Kuros Biosciences Expands into Extremities Markets
English 18.5 KB
2024-11-19 01:00
Kuros Biosciences Expands into Extremities Markets
English 16.1 KB
2024-10-10 02:00
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow brea…
English 16.3 KB
2024-08-08 07:00
Kuros Biosciences Reports First Half of 2024 Results
English 37.6 KB
2024-08-08 02:00
Kuros Biosciences Reports First Half of 2024 Results
English 33.0 KB
2024-06-25 07:00
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 17.2 KB
2024-06-25 02:00
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 14.9 KB

Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kuros Biosciences Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-23 N/A Executive member Sell None 1,264,800.00 CHF
2025-04-17 N/A Executive member Sell None 13,344.49 CHF
2025-03-18 N/A Non-Executive member Buy None 38,200.00 CHF
2024-12-11 N/A Executive member Sell None 4,702,500.00 CHF
2024-11-15 N/A Non-Executive member Buy None 925,210.00 CHF
2024-11-14 N/A Non-Executive member Sell None 592,000.00 CHF
2024-11-12 N/A Executive member Sell None 13,890.86 CHF
2024-09-25 N/A Executive member Sell None 8,226,000.00 CHF
2024-09-25 N/A Non-Executive member Sell None 3,656,000.00 CHF
2024-09-24 N/A Non-Executive member Buy None 223,720.00 CHF

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.